CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Vortioxetine (Lu AA21004)drug
Likely dose
Vortioxetine (Lu AA21004) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00761306
NCT00761306Phase 2Completed
CompareCT.gov

A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder

H. Lundbeck A/S·interventional·Posted Sep 29, 2008·Updated Jan 29, 2014

In Brief

A Phase 2 clinical trial evaluating Vortioxetine (Lu AA21004) for Major Depressive Disorder. Completed, enrolled 74 participants.

Detailed Summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 29, 2008
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago

Interventions

Vortioxetine (Lu AA21004)drug

5 or 10 mg/day; tablets; orally